Akari Therapeutics is a biopharmaceutical company focused on developing treatments for rare autoimmune and inflammatory diseases. Its lead product candidate, Nomacopan (formerly Coversin), is a dual inhibitor of complement component 5 (C5) and leukotriene B4 (LTB4), currently in clinical trials for bullous pemphigoid, thrombotic microangiopathy, and other indications.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.